Drug intelligence / Profile preview

P4899

Development stage: Unknown
Lead developer: Oscotec

Overview

P4899 (OSCOTEC): sourced facts only. name: "In this study, we demonstrate anti-chemoresistance and anti-fibrotic activities of P4899, a potent and selective NUAK1/2 dual inhibitor, in pancreatic cancer." [DOI:10.1158/1538-7445.am2025-3077]; target: "In this study, we demonstrate anti-chemoresistance and anti-fibrotic activities of P4899, a potent and selective NUAK1/2 dual inhibitor, in pancreatic cancer." [DOI:10.1158/1538-7445.am2025-3077]; developer: "OSCOTEC Inc., Seongnam-si, Republic of Korea." [DOI:10.1158/1538-7445.am2025-3077]

Targets

NUAK1 (NUAK family SNF1-like kinase 1)

Beyond the preview

Go deeper on P4899.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P4899.